The Canadian Cohort Obstructive Lung Disease


Abstract Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in Canada. COPD is not just a disease of men, nor is it solely a disease in old age. Women have been underrepresented and early disease has not been studied. Underdiagnosis of COPD remains a significant problem, and it may indicate an unmet healthcare need. This can potentially results not only in a patient been misinformed, but can lead to incorrect management.

Epidemiological research is needed to develop a framework to combat this major health problem, by better characterization of the population of men and women at risk and patients with early disease, by better understanding which factors modifiable through health interventions are related to health perception (health-related quality of life) and disease evolution.

This will be possible through a nationwide study, the Canadian Cohort Obstructive Lung disease (CanCOLD), a prospective longitudinal study. The CanCOLD study is built on the current ongoing prevalence nationwide study, the Canadian Obstructive Lung disease "COLD" study.

The CanCOLD will be the first study to assess prevalence of disease across Canada and its consequence in men and women, and to evaluate a conceptual model of disease severity based on patient's health perception (health-related quality of life). Ultimately, this project will extend to a longitudinal follow up (3 years or beyond) and will allow to have a better understanding of the lifestyle risk factors, not only smoking but also diet, physical activity, and co morbid conditions. This will be a great asset to shift from management of a single risk factor (tobacco control) to total COPD risk management. The results of the study will greatly help to assist decision makers in developing policies to improve the diagnosis, the management of COPD and to optimize health care services use.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2022

Arms, Groups and Cohorts

  • Group 1
    • COPD moderate-severe(GOLD2-4)(post-BD FEV1/FVC<0.70 and FEV1<80% of pred.)
  • Group 2
    • COPD mild (GOLD1)(post-BD FEV1/FVC<0.70 AND FEV1>=80% of pred.)
  • Group 3
    • COPD at risk (ever smoker with post-BD FEV1/FVC>=0.70)
  • Group 4
    • “Healthy control” never smokers without respiratory disease (post-BD FEV1/FVC>=0.70.

Clinical Trial Outcome Measures

Primary Measures

  • What risk factors other than smoking determine the development and progression of COPD.
    • Time Frame: One visit a year every 18 months

Secondary Measures

  • What are the combinations of the disease and patient attributes that differentiate individuals (men/women) with COPD as they relate to relevant outcomes (symptoms, exacerbations, disease progression or death)
    • Time Frame: One visit a year 18 months
  • Is early detection of COPD with spirometry meaningful according to sex and ageing.
    • Time Frame: One visit a year 18 months

Participating in This Clinical Trial

Inclusion Criteria

  • All the subjects have taken part in the COLD study, a true population based prevalence study. Subjects must have an inclusion criteria of 40 years and older to participate in the COLD study.

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • McGill University Health Centre/Research Institute of the McGill University Health Centre
  • Collaborator
    • Canadian Institutes of Health Research (CIHR)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jean Bourbeau, MD, M.Sc. – McGill University Health Centre/Research Institute of the McGill University Health Centre
  • Overall Official(s)
    • Jean Bourbeau, M.D., M.Sc., Principal Investigator, McGill University Health Centre/Research Institute of the McGill University Health Centre
    • Wan Tan, M.D., Principal Investigator, CAAA University of British Columbia
    • François Maltais, M.D., Principal Investigator, CFBA Université Laval
    • Shawn Aaron, M.D., M.Sc., Principal Investigator, OHGC Ottawa Hospital General Campus
    • Denis O’Donnell, M.D., Principal Investigator, CEDA Queen’s University (Kinsgston)
    • Darcy D Marciniuk, M.D., Principal Investigator, CCAA University of Saskatchewan
    • Robert Cowie, M.D., Principal Investigator, CBBA University of Calgary
    • Kenneth R. Chapman, M.D., M.Sc., Principal Investigator, CEAA University of Toronto
    • Paul Hernandez, M.D., Principal Investigator, CHAA Dalhousie University (Nova Scotia)
    • Mark J. FitzGerald, M.D., Principal Investigator, CAAA University of British Columbia
    • Donald Sin, M.D., Principal Investigator, CAAA University of British Columbia
    • Andrea Benedetti, Ph.D., Principal Investigator, INUD McGill University Healty Center
    • Yves Lacasse, M.D., M.Sc., Principal Investigator, CPVR Institut universitaire de cardiologie et de pneumologie de Québec
    • Pierre Ernst, M.D., Principal Investigator, McGill University
    • Harvey Coxson, M.D., Principal Investigator, University of British Columbia
    • Roger Goldstein, M.D., Principal Investigator, CEAA University of Toronto
    • Carlo Marra, Ph.D., Principal Investigator, CAAA University of British Columbia

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.